Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:50:04.022Z.
Consensus retrieved: 2026-10-06T16:52:36.984Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:50:04.022Z.
Quote observation: 2026-10-06T19:45:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 86570ebe4e10e0745eed5accab5992648689f404d3311a046465d3de5892ac1d
Forward PE Ratio (N/A) = Dated Quote Price ($36.33) / Consensus Forward EPS ($-4.60)
FORWARD PE RATIO
N/A
Xenon Pharmaceuticals Inc.
Market Cap
$3.51B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | $3.51B | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | N/A |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.54B | N/A |
| Veracyte, Inc. (VCYT)vs › | $3.55B | 23.26 |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.46B | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.43B | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 32.00 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.67B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $36.33, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.60 | $-4.89 – $-4.28 | 13 | n/m |
| 2027-12-31 | $-4.68 | $-5.53 – $-3.65 | 13 | n/m |
| 2028-12-31 | $-3.32 | $-5.48 – $0.15 | 11 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
